{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:04:17Z","timestamp":1773745457610,"version":"3.50.1"},"reference-count":33,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Radioactive iodine (RAI) is an established therapy for thyroid cancer (TC). The aim of this study was to evaluate the prognosis and disease characteristics based on initial RAI therapy using image findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed the clinical records of 290 TC patients who received initial therapeutic RAI therapy following total thyroidectomy for ablation and treatment between 2010 and 2021. Patients were classified into 3 groups based on the 131I whole-body scintigraphy (WBS) combined with morphological imaging records: non-DM, RAI-non-avid DM, and RAI-avid DM. Progression-free survival (PFS) and overall survival were assessed in each group. Normalized indices were calculated automatically using dedicated software for each patient on WBS. 131I-avid lesions were defined as areas with uptake exceeding the mean + 2 SDs of the reference regions of interest placed at the head-cervical, thoracic, and abdominal-pelvis regions, Watabe proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 5-year and 7-year survival rates for the non-DM, RAI-non-avid DM, and RAI-avid DM groups were 98% to 95%, 86% to 78%, and 82% to 82%, respectively. Average count of 131I-avid area was identified as a significant prognostic factor for PFS, being independent of age, distant metastatic pattern, histological subtype, and T classification. Retreatment was preferably performed within 2 years after the initial RAI therapy, as this period appears to be critical for efficacy. Additionally, the site of metastases was a strong prognostic determinant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Precise imaging evaluation of the initial RAI therapy may help predict the prognosis during the first 5 years, contributing to more effective comprehensive treatment approaches for long-term management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaf568","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:09:23Z","timestamp":1760447363000},"page":"1004-1020","source":"Crossref","is-referenced-by-count":1,"title":["Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7684-466X","authenticated-orcid":false,"given":"Rieko","family":"Nakatani","sequence":"first","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]},{"name":"Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine , Kyoto 602-8566 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8658-2395","authenticated-orcid":false,"given":"Tadashi","family":"Watabe","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6289-3778","authenticated-orcid":false,"given":"Atsunori","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]},{"name":"Department of Adipose Management, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6966-0924","authenticated-orcid":false,"given":"Toru","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6699-8796","authenticated-orcid":false,"given":"Takashi","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]},{"name":"Department of Medical Technology, The University of Osaka Hospital , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6630-3784","authenticated-orcid":false,"given":"Hidetaka","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]},{"name":"Department of Medical Technology, The University of Osaka Hospital , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1025-1861","authenticated-orcid":false,"given":"Hiroyuki","family":"Kurakami","sequence":"additional","affiliation":[{"name":"Department of Medical Innovation, The University of Osaka Hospital , Suita 565-0871 ,","place":["Japan"]},{"name":"Institute for Clinical and Translational Science, Nara Medical University , Kashihara 634-8522 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6011-2378","authenticated-orcid":false,"given":"Yukiko","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5947-8621","authenticated-orcid":false,"given":"Michio","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0444-2933","authenticated-orcid":false,"given":"Yoh","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0851-9603","authenticated-orcid":false,"given":"Iichiro","family":"Shimomura","sequence":"additional","affiliation":[{"name":"Department of Metabolic Medicine, Graduate School of Medicine, The University of Osaka , Suita 565-0871 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"676","key":"2026031619565026900_dgaf568-B1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1259\/0007-1285-57-676-323","article-title":"Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience","volume":"57","author":"Brown","year":"1984","journal-title":"Br J Radiol"},{"issue":"5","key":"2026031619565026900_dgaf568-B2","first-page":"220","article-title":"A plan for analysis of the biologic factors involved in experimental carcinogenesis of the thyroid by means of radioactive isotopes","volume":"8","author":"Hertz","year":"1946","journal-title":"Bull New Engl Med Cent"},{"issue":"2","key":"2026031619565026900_dgaf568-B3","first-page":"71","article-title":"The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M. Seidlin, M. D. (1895-1955) and his celebrated patient","volume":"14","author":"Siegel","year":"1999","journal-title":"Cancer Biother Radiopharm"},{"issue":"1","key":"2026031619565026900_dgaf568-B4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"12","key":"2026031619565026900_dgaf568-B5","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"ESMO guidelines committee. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"2026031619565026900_dgaf568-B6","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","article-title":"Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer","volume":"97","author":"Mazzaferri","year":"1994","journal-title":"Am J Med"},{"issue":"4","key":"2026031619565026900_dgaf568-B7","first-page":"598","article-title":"Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma","volume":"37","author":"Schlumberger","year":"1996","journal-title":"J Nucl Med"},{"issue":"8","key":"2026031619565026900_dgaf568-B8","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026031619565026900_dgaf568-B9","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/thy.2012.0654","article-title":"Long-term prognosis of differentiated thyroid cancer with lung metastasis in Korea and its prognostic factors","volume":"24","author":"Cho","year":"2014","journal-title":"Thyroid"},{"issue":"3","key":"2026031619565026900_dgaf568-B10","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1089\/thy.2008.0186","article-title":"The importance of age over radioiodine avidity as a prognostic factor in differentiated thyroid carcinoma with distant metastases","volume":"19","author":"Mihailovic","year":"2009","journal-title":"Thyroid"},{"issue":"7","key":"2026031619565026900_dgaf568-B11","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/cncr.22956","article-title":"Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis","volume":"110","author":"Sampson","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"2026031619565026900_dgaf568-B12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1507\/endocrj.EJ22-0463","article-title":"Long-term outcomes and prognostic factors of patients with lung metastases from differentiated thyroid cancer after radioiodine therapy in Japan","volume":"70","author":"Akatani","year":"2023","journal-title":"Endocr J"},{"issue":"7","key":"2026031619565026900_dgaf568-B13","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s00259-022-05697-w","article-title":"Bone metastases from differentiated thyroid carcinoma: heterogenous tumor response to radioactive iodine therapy and overall survival","volume":"49","author":"Jannin","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"2026031619565026900_dgaf568-B14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/thy.2022.0353","article-title":"Disease-specific survival trends for patients presenting with differentiated thyroid cancer and distant metastases in the United States, 1992-2018","volume":"33","author":"Wilhelm","year":"2023","journal-title":"Thyroid"},{"key":"2026031619565026900_dgaf568-B15","year":"2020"},{"key":"2026031619565026900_dgaf568-B16","first-page":"1121","volume-title":"Perez & Brady's Principles and Practice of Radiation Oncology","author":"Amdur","year":"2018","edition":"7th"},{"issue":"5","key":"2026031619565026900_dgaf568-B17","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1089\/thy.2011.0311","article-title":"Subcellular distribution of the sodium iodide symporter in benign and malignant thyroid tissues","volume":"22","author":"Kollecker","year":"2012","journal-title":"Thyroid"},{"issue":"3","key":"2026031619565026900_dgaf568-B18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/ncpendmet0449","article-title":"Defects in iodide metabolism in thyroid cancer and implications for the follow-up and treatment of patients","volume":"3","author":"Schlumberger","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"7","key":"2026031619565026900_dgaf568-B19","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1089\/thy.2020.0826","article-title":"A joint statement from the American thyroid association, the European association of nuclear medicine, the European thyroid association, the society of nuclear medicine and molecular imaging on current diagnostic and theranostic approaches in the management of thyroid cancer","volume":"31","author":"Gulec","year":"2021","journal-title":"Thyroid"},{"key":"2026031619565026900_dgaf568-B20","doi-asserted-by":"crossref","unstructured":"Nakatani R, Watabe T, Fukuhara A, et al \u00a0Datasets and supplemental materials from: Initial evaluation of radioiodine therapy using Imaging for long-term prognosis in thyroid cancer: A retrospective study. University of Osaka Institutional Knowledge Archive (OUKA) repository. Deposited September 18, 2025","DOI":"10.1210\/clinem\/dgaf568"},{"key":"2026031619565026900_dgaf568-B21","first-page":"50","volume-title":"TNM Classification of Malignant Tumours","author":"Brierley","year":"2016","edition":"8th ed."},{"key":"2026031619565026900_dgaf568-B22","first-page":"881","volume-title":"AJCC Cancer Staging Manual","author":"American Joint Committee on Cancer (AJCC)","year":"2017","edition":"8th ed"},{"key":"2026031619565026900_dgaf568-B23","volume-title":"General Rules for the Description of Thyroid Cancer","author":"Japan Association of Endocrine Sugery and The Japanese Society of Thyroid Pathology","year":"2019","edition":"8th"},{"issue":"6","key":"2026031619565026900_dgaf568-B24","doi-asserted-by":"crossref","first-page":"872","DOI":"10.2967\/jnumed.111.098699","article-title":"Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors","volume":"53","author":"Yanagawa","year":"2012","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"2026031619565026900_dgaf568-B25","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"issue":"3","key":"2026031619565026900_dgaf568-B26","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2026031619565026900_dgaf568-B27","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2184::AID-CNCR21>3.0.CO;2-U","article-title":"131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma","volume":"78","author":"Sisson","year":"1996","journal-title":"Cancer"},{"issue":"3","key":"2026031619565026900_dgaf568-B28","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-15-0296","article-title":"Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors","volume":"173","author":"Song","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026031619565026900_dgaf568-B29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/cen.13489","article-title":"Prognostic indicators of outcomes in patients with lung metastases from differentiated thyroid carcinoma during long-term follow-up","volume":"88","author":"Sohn","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2026031619565026900_dgaf568-B30","doi-asserted-by":"crossref","first-page":"e230086","DOI":"10.1530\/ETJ-23-0086","article-title":"Bone metastases from differentiated thyroid cancer: characteristics and prognostic factors in a multicenter series","volume":"12","author":"Pinar-Gutierrez","year":"2023","journal-title":"Eur Thyroid J"},{"issue":"1","key":"2026031619565026900_dgaf568-B31","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1089\/thy.2013.0367","article-title":"Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation","volume":"24","author":"Ito","year":"2014","journal-title":"Thyroid"},{"issue":"11","key":"2026031619565026900_dgaf568-B32","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1089\/thy.2019.0211","article-title":"Active surveillance versus immediate surgery: questionnaire survey on the current treatment strategy for adult patients with low-risk papillary thyroid microcarcinoma in Japan","volume":"29","author":"Sugitani","year":"2019","journal-title":"Thyroid"},{"issue":"10","key":"2026031619565026900_dgaf568-B33","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1002\/lary.25295","article-title":"RAI thyroid bed uptake after total thyroidectomy: a novel SPECT-CT anatomic classification system","volume":"125","author":"Zeuren","year":"2015","journal-title":"Laryngoscope"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf568\/64706787\/dgaf568.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/4\/1004\/64706787\/dgaf568.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/4\/1004\/64706787\/dgaf568.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T23:57:08Z","timestamp":1773705428000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/4\/1004\/8286442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,15]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf568","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,10,15]]}}}